Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Contract Pharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrPiramal Pharma Revenue Increases 12% YoY in Q1
FrCellectis' UCART22 Granted ODD and RPDD Status by FDA
DoPace Life Sciences Completes Successful FDA Inspection of Operations in Oakdale, MN
DoEmmes, Miimansa AI Partner on Generative AI in Clinical Research
DoStuart Therapeutics Taps Dr. Lukas Scheibler as Chief Science & Technology Officer
DoAlmac Completes FDA Inspection at Charnwood, UK Facilities
DoCapra Biosciences Receives $7.5M Project Agreement
DoCatalyst Grants Kye Exclusive Canadian Commercial Rights to AGAMREE
DoXavo Welcomes Plexium as Its Latest Client
DoNeuraxpharm to Utilize Veeva Quality Applications
MiRxSource to Relocate to Larger Facility in West Deptford, NJ
MiCarbogen Amcis Completes FDA Inspections at Two Manufacturing Sites
MiJohnson & Johnson Strengthens Position in Italy with €580M Investment
MiAgilent to Acquire North American CDMO BioVectra
MiDe Motu Cordis Expands DPI Partnership with Catalent
MiIDT Bolsters CRISPR Portfolio with SeQure Dx Licensing Deal
MiScorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign
MiBeacon Therapeutics Appoints New CEO and CFO
DiViroCell Signs Master Services Agreement with Prominent Cancer Center
DiMidEuropa Agrees to Acquire Famar
DiPace Life Sciences Names Head of Commercial
DiGalderma Granted Manufacturing License Updates for New Biologics Capabilities
DiNordic Bioproducts Receives EXCiPACT Certification for MCC Production at Lappeenranta Facility
DiNavin Molecular Expands GMP Manufacturing Capabilities
DiEmmaus Life Sciences Appoints Willis C. Lee as CEO